Table 2.

Antimicrobial Exposure During Follow-Up for the 1,299,056 Study Patients

Antimicrobial	No. of Patients	Current Use (Person-Years)a	Recent Use (Person-Years)b
Amoxicillin	352,614	56,886	109,142
Amoxicillin-clavulanic acid	309,593	45,922	85,272
Cefuroxime	182,786	25,179	47,647
Clarithromycin	245,865	34,524	66,206
Doxycycline	254,535	49,998	65,446
Levofloxacin	331,891	52,383	97,197
Moxifloxacin	226,375	29,937	58,374
Telithromycin	95,887	10,745	24,210
Multiple study antimicrobialsc	180,116	15,915	40,374

Data in this table are shown for all the patients in the study. However, patients could have had exposure to more than one study drug during their follow-up and thus could be counted in the multiple study antimicrobials group as well as in one or more single antimicrobial lines; therefore, the numbers in the “No. of Patients” column add up to more than the total number of patients in the study.

^aCurrent use is defined as the prescribed duration of the antimicrobial plus 30 days.

^bRecent use is defined as a duration of 90 days after the end of current use of the antimicrobial.

^cMultiple study antimicrobials is defined as current use of two or more study antimicrobials on the same day or recent use of two or more study antimicrobials on the same day.